Rigshospitalet
- Country
- 🇩🇰Denmark
- Ownership
- Private
- Established
- 1757-03-30
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.rigshospitalet.dk
Clinical Trials
1.2k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (766 trials with phase data)• Click on a phase to view related trials
This Study Aims to Clarify the Prevalence and Characteristics of Neuropathy, Along With Associated Paraclinical Findings in Patients With Waldenström's Macroglobulinemia (WM) in a Cohort of WM Patients to Optimize the Diagnostic Process
- Conditions
- Waldenstrom MacroglobulinaemiaPeripheral Neuropathies
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 90
- Registration Number
- NCT07160270
- Locations
- 🇩🇰
Copenhagen Neuromuscular Center, Rigshospitalet Blegdamsvej., København Ø, Denmark
Long-term Systematic Follow-up of Patients With Klinefelter Syndrome Followed at the Department of Growth and Reproduction, Rigshospitalet
- Conditions
- Klinefelter Syndrome
- First Posted Date
- 2025-08-26
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 300
- Registration Number
- NCT07142135
- Locations
- 🇩🇰
Copenhagen University Hospital, Rigshospitalet, Department of Growth and Reproduction, Copenhagen, Denmark
Monitoring Neurocognitive Dysfunction and the Impact of Metabolism and Physical Capacity After Paediatric HSCT
- Conditions
- Stem Cell TransplantLate EffectNeurocognitive DysfunctionPaediatric PatientsMetabolic SyndromePhysical Capacity
- First Posted Date
- 2025-08-24
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 175
- Registration Number
- NCT07140445
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Capital Region, Denmark
Monitoring Fatigue In Daily Life In Adults With Cerebral Palsy or Acquired Brain Injury
- Conditions
- Fatigue SymptomFatigue IntensityCerebral Palsy (CP)Acquired Brain Injury Including StrokeFatigue, MentalFatigue
- First Posted Date
- 2025-08-22
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 120
- Registration Number
- NCT07135791
- Locations
- 🇩🇰
Neurorehabilitation Research and Knowledge Centre, Rigshospitalet, Glostrup, Denmark
European Registry Study on Lymphatic Interventions
- Conditions
- Lymphatic DisordersPlastic BronchitisProtein Losing EnteropathyChylothoraxLymphatic Abnormalities
- First Posted Date
- 2025-08-20
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 500
- Registration Number
- NCT07131293
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
- Prev
- 1
- 2
- 3
- 4
- 5
- 198
- Next
News
Novel Trial Compares Low-Dose Thrombolysis Methods for Pulmonary Embolism Treatment
A groundbreaking clinical trial is investigating three different treatment approaches for intermediate-high risk pulmonary embolism (PE): standard heparin therapy, low-dose thrombolysis, and ultrasound-assisted thrombolysis (USAT). The study aims to enroll 210 patients and will evaluate the effectiveness of these interventions using refined Miller scores to measure thrombus reduction.
Glofitamab Plus Polatuzumab Demonstrates Durable Responses in Relapsed/Refractory LBCL
Glofitamab combined with polatuzumab vedotin shows high response rates and durable remissions in heavily pretreated relapsed/refractory large B-cell lymphoma (LBCL).
Dostarlimab Shows Superior Survival Outcomes Across Multiple Endometrial Cancer Molecular Subgroups in Phase 3 RUBY Trial
The phase 3 RUBY trial demonstrated that dostarlimab combined with carboplatin and paclitaxel significantly improved progression-free survival and overall survival in patients with advanced or recurrent endometrial cancer across multiple molecular subgroups.